期刊文献+

碱性成纤维细胞生长因子对大鼠肩袖损伤术后冈上肌腱生物力学的影响 被引量:2

Biomechanics effect of basic fibroblast growth factor on supraspinatus tendon of rats following surgery for rotator cuff tears
下载PDF
导出
摘要 目的评价碱性成纤维细胞生长因子(BFGF)对大鼠肩袖损伤重建术后腱-骨界面愈合的修复效果。方法 135只Wistar大鼠分为高剂量组、低剂量组和空白组各45只,取右侧肩袖大结节止点处横断撕裂肩袖冈上肌腱全层,6周后原位缝合,腱骨界面注射以纤维蛋白胶为载体的BFGF。缝合术后1、2、3周,每次处死各组15只大鼠,取右上肢冈上肌腱标本行腱-骨界面最大载荷百分比、刚度及刚度百分比生物力学测试。结果在术后1、2及3周,高剂量组及低剂量组的冈上肌腱术侧/健侧最大载荷百分比均高于空白组(P<0.05);在术后2周及3周,高剂量组的冈上肌腱术侧/健侧最大载荷百分比高于低剂量组(P<0.05)。术后2周及3周,高剂量组的刚度均高于低剂量组及空白组(P<0.05);术后1周及2周,高剂量组/空白组与低剂量组/空白组的刚度百分比均高于高剂量组/低剂量组(P<0.05)。结论 BFGF可提高腱-骨界面的最大载荷百分比、刚度,诱导断面再生成直接止点的复杂结构促进肩袖损伤的愈合。 Objective To evaluate the repairing effect of basic fibroblast growth factor( BFGF) on tendon-bone healing of rats following the reconstruction for rotator cuff tears. Methods A total of 135 Wistar rats were divided into high-dose group,low-dose group and blank group,with 45 rats in each group. The full-thickness supraspinatus tendon was transversely torn at the insertion of greater tuberosity of right lateral rotator cuff,suture in situ was performed six weeks later,and BFGF with fibrin sealant as a carrier was applied to tendon-bone injection. Fifteen rats in each group were sacrificed per time in the first,second and third week after suture,respectively. The supraspinatus tendon samples of right upper extremity were collected for the biomechanics test of maximum loading percentage,stiffness and percentage of stiffness of tendon-bone junction. Results The maximum loading percentages of contralateral to ipsilateral supraspinatus tendon of high-and low-dose groups were all significantly higher than those of blank group in the first,second and third week after operation( P 〈 0. 05). The maximum loading percentages of contralateral to ipsilateral supraspinatus tendon of high-dose group were significantly higher than those of low-dose group in the second and third week after operation( P 〈 0. 05). The stiffness of high-dose group was significantly higher than that of low-dose group or blank group in the second and third week after operation( P 〈 0. 05). The percentages of stiffness of high-dose group to blank group and low-dose group to blank group were significantly higher than that of high-dose group to low-dose group in the first and second week after operation( P 〈 0. 05). Conclusion BFGF might increase the maximum loading percentage and stiffness of tendon-bone junction,transversely regenerate the direct insertion of complex structure,and promote the healing of rotator cuff tears.
出处 《广西医学》 CAS 2015年第11期1540-1542,共3页 Guangxi Medical Journal
基金 河北省医学科学研究重点课题(ZL20140293)
关键词 肩袖损伤 碱性成纤维细胞生长因子 腱-骨愈合 生物力学 大鼠 Rotator cuff tears Basic fibroblast growth factor Tendon-bone healing Biomechanics Rat
  • 相关文献

参考文献2

二级参考文献7

  • 1Gy?rgy Bodoky,Constanta Timcheva,David Spigel,Phillip Stella,Tudor Ciuleanu,G. Pover,N. Tebbutt.A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy[J].Investigational New Drugs.2012(3)
  • 2Gregory L. Beatty,Drew A. Torigian,E. Gabriela Chiorean,Babak Saboury,Alex Brothers,Abass Alavi,Andrea B. Troxel,Weijing Sun,Ursina R. Teitelbaum,Robert H. Vonderheide,Peter J. O’Dwyer.A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma[J].Clinical Cancer Research.2013(22)
  • 3Shinichi Yabuuchi,Shweta G. Pai,Nathaniel R. Campbell,Roeland F. de Wilde,Elizabeth De Oliveira,Preethi Korangath,Mirte M. Streppel,Zeshaan A. Rasheed,Manuel Hidalgo,Anirban Maitra,N.V. Rajeshkumar.Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer[J].Cancer Letters.2013(1)
  • 4Mohamed A. Khalil,Wei Qiao,Peter Carlson,Binsah George,Milind Javle,Michael Overman,Gauri Varadhachary,Robert A. Wolff,James L. Abbruzzese,David R. Fogelman.The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer[J].Investigational New Drugs.2013(5)
  • 5Philippe Rougier,Hanno Riess,Robert Manges,Petr Karasek,Yves Humblet,Carlo Barone,Armando Santoro,Sylvie Assadourian,Laurence Hatteville,Philip A. Philip.Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer[J].European Journal of Cancer.2013(12)
  • 6Uwe Pelzer,Ingo Schwaner,Jens Stieler,Mathias Adler,J?rg Seraphin,Bernd D?rken,Hanno Riess,Helmut Oettle.Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group[J].European Journal of Cancer.2011(11)
  • 7Henry Q.Xiong,Gauri R.Varadhachary,Joan C.Blais,Kenneth R.Hess,James L.Abbruzzese,Robert A.Wolff.Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer[J].Cancer.2008(8)

共引文献10

同被引文献15

引证文献2

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部